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Open acAbstract Aim: To compare triage strategies using different human papillomavirus (HPV)
consensus and genotyping tests and a p16INK4a test.
Methods: 1228 women referred with a borderline or single mildly dyskaryotic smear. Samples
were taken at colposcopy using PreservCyt. Tests included Hybrid Capture 2, Abbott Real-
Time PCR, BD HPV, Cobas 4800, PreTect HPV-Proofer, APTIMA and p16INK4a. Results
were based on the worst histology within 9 months.
Results: 97/1228 (7.9%) women had CIN3+ (203/1228 (17%) CIN2+). HPV testing alone
using Hybrid Capture 2, Abbott RealTime PCR, BD HPV, Cobas 4800 or APTIMA had a
sensitivity for CIN3+ ranging from 99.0% to 100.0% and speciﬁcity for <CIN2 from 23.3%
to 34.7%. p16INK4a had a sensitivity of 86.8% and speciﬁcity of 50.7%. PreTect HPV-Proofer
had a sensitivity of 85.1% and speciﬁcity of 73.2%. Testing for HPV type 16 only had sensi-
tivities ranging from 66.0% to 75.5% and speciﬁcities from 81.3% to 87.6%. Dual testing with
HPV type 16 combined with p16INK4a gave a high sensitivity for CIN3+ (78.7% to 98.0%) and
speciﬁcity for <CIN2 of 58.6% to 81.5%.18
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2180 D. Mesher et al. / European Journal of Cancer 49 (2013) 2179–2186Conclusions: Triage with sensitive HPV testing assays can substantially reduce the number of
unnecessary referrals in women with low grade cytology with virtually no loss of sensitivity.
Even greater gains can be made if p16 and type 16 are used, but some cases of CIN2 will
be missed. In both cases short term surveillance will be needed.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
At least one of 14 recognised high risk types of the
human papillomavirus (HPV) is present in almost all
cervical cancers and persistent HPV infection with such
high risk types is a necessary cause of disease.1,2
Cervical cytology testing is used by many established
screening programmes with wide variation across Eur-
ope in the proportion of women referred to repeat cytol-
ogy and colposcopy.3 Low-grade cytology is associated
with low positive predictive value (PPV) and many
unnecessary colposcopic referrals. It has been suggested
that triage tests are needed to ensure that women with
high-grade cervical disease are identiﬁed but, at the same
time, avoiding unnecessary over-referral to colpos-
copy.4–7
Triage is now routine in the United States of America
(USA)4,6 and many other countries. Within England
and Wales HPV testing is being introduced into the
NHS Cervical Screening Programme (NHSCSP) for
women with a borderline or mildly dyskaryotic cervical
cytology result.8,9 Women who test positive for HPV tri-
age will be referred to colposcopy and treated where
necessary. However, it is not clear which HPV tests
are most suitable for triage of cytology. We present data
from two studies for women who were referred with a
low-grade cytology and have been tested by repeat cytol-
ogy and a range of HPV tests. We aim to compare dif-
ferent triage strategies among these women using
potential triage tests including HPV DNA, HPV
RNA, HPV genotyping and p16INK4a tests.2. Materials and methods
This analysis was restricted to women referred with a
borderline or single mildly dyskaryotic smear who were
enrolled in one of two studies (Fig. 1). All women
included were referred with one or more abnormal cer-
vical smears and had not been previously treated for cer-
vical intraepithelial neoplasia (CIN). No HPV testing
had been performed as part of routine screening of these
women:
Predictors phase 1: 953 women were included in the
original study and 559 (59%) were referred with a bor-
derline or single mildly dyskaryotic smear. The details
of the cohort are described elsewhere.10 Samples were
collected at colposcopy using PreservCyt for repeat
cytology and HPV testing by Hybrid Capture 2, PreTectHPV-Proofer, APTIMA, Abbott RealTime and
p16INK4a (tests described in full below).
Predictors phase 2: 1099 women were included in the
original study and 669 (61%) were referred with a bor-
derline or single mildly dyskaryotic smear. Two cervical
samples were taken because the number of tests pro-
posed required more aliquots than could be obtained
from a single sample. As in Predictors 1, samples were
collected for repeat cytology and HPV testing at colpos-
copy using PreservCyt. Full details of the cohort are
described elsewhere.11 HPV testing was performed using
Hybrid Capture 2, PreTect HPV-Proofer, APTIMA,
Abbott RealTime, p16INK4a, Cobas 4800 and BD HPV
tests (tests described in full below).
Where appropriate, histology samples for both stud-
ies were obtained at colposcopy. In addition, results
from all histology taken within 9 months of the initial
colposcopy were collected from the hospital. If histology
was not taken due to a normal colposcopy then the his-
tology result was considered negative. All available his-
tology was centrally reviewed, blinded to the original
result, and where discrepant readings occurred, further
review was undertaken. Results presented here are based
on the worst reviewed histology within 9 months of the
initial colposcopy. Unless otherwise speciﬁed, all assays
were conducted within the Wolfson Institute under the
direction of LH and GT.
2.1. HPV testing
DNA based detection assays:
 Hybrid Capture 2 (Qiagen) detecting 13 HR-HPV
genotypes collectively. The assay is based on the
hybridisation of HPV DNA to a 13 HR HPV RNA
probe cocktail. Readings over 1 RLU are considered
positive.
DNA based partial genotyping assays:
 Abbott RealTime High Risk HPV Assay (Abbott
Molecular) is a qualitative multiplex real-time test
which identiﬁes HPV 16 and 18 separately and the
remaining high risk types as a group (31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66 and 68).
 The BD HPV test (BD Diagnostics) is a real time
PCR test which concurrently detects 14 HR HPV
types. Seven HPV types (16, 18, 31, 45, 51, 52 and
59) are individually identiﬁed and the remaining
HPV type results are grouped as (33, 56, 58, 66) or
Predictors 1 study
referred for colposcopy
n=999
Predictors 2 study
referred for colposcopy
n=1117
18 non eligible
- Did not give full consent: 4
- Referred without an abnormal smear: 3
- Sample delayed: 1
- Sample returned to cytopathology: 1
- Sample lost due to leakage: 1
- No sample received: 4
- Sample lost: 4
46 non eligible
- Did not give full consent: 1
- Referred without an abnormal smear: 5
- Previous treatment: 10
- Pregnancy: 3
- Insufficient material: 27
Predictors 1 study
eligible women
n=953
Predictors 2 study
eligible women
n=1099
Combined studies
eligible women
n=2052
824 not referred with borderline or single 
mildly dyskaryosis
Combined for analysis
n=1228
Borderline dyskaryosis
n=287
Single mild dyskaryosis
n=941
Fig. 1. Study ﬂow chart.10,11
D. Mesher et al. / European Journal of Cancer 49 (2013) 2179–2186 2181(35, 39, 68). At the time of writing, this test is not yet
commercially available and the ﬁnal clinical cut-oﬀ is
currently under review to maximise test speciﬁcity.
 Cobas 4800 (RocheDiagnostics) is a qualitative in vitro
test for the detection of 14HRHPV types. The test sep-
arately identiﬁes HPV 16 and 18 while concurrently
detecting 12 remaining high risk types as a group (31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68).
RNA based detection assays:
 PreTect HPV-Proofer (NorChip) detects RNA from
E6/E7 region of the HPV genome. Assayed at The
Doctors’ Laboratory, London. PreTect HPV-Proofer
separately identiﬁes ﬁve high risk HPV types
(16,18,31,33 and 45) using proprietary primer sets
by a NASBA technique.
 APTIMA (Gen-Probe) assay for the detection of E6/
E7 mRNA expression of 14 HR HPV types. Predic-
tors 1 testing was performed by Gen-Probe. Predic-
tors 2, testing for HPV positivity was performed atthe Wolfson Institute (LH/GT). Predictors 2 samples
were additionally tested at Gen-Probe with HPV type
speciﬁc tests using an AHPV-GT assay for HPV 16
and 18/45 (not commercially available as yet).
Other tests:
 p16INK4a (CINtec Cytology, mtm laboratories) immu-
nocytochemical detection of overexpression of the
p16INK4a tumour suppressor gene and scoring using
nuclear morphology. Immunostaining was done at
the mtm laboratory. Reporting of CINtec p16INK4a
cytology was carried out blindly by CB. For Predic-
tors 1, the p16INK4a testing was always performed
after the other tests and therefore there was not
always suﬃcient material.2.2. Statistical analysis
We considered the worst histology ﬁnding within
9 months of the baseline visit. The main endpoint for
2182 D. Mesher et al. / European Journal of Cancer 49 (2013) 2179–2186sensitivity was taken as CIN3+ (CIN2+ was also con-
sidered). Speciﬁcity is only reported for <CIN2, as we
do not consider the detection of CIN2 to be a ‘false
positive’.
We considered pre-deﬁned triage strategies which
included single testing for each of the above tests;
HPV testing in combination with p16INK4a (i.e. positive
for both HPV test and p16INK4a); testing for HPV type
16; testing for HPV types 16 and/or 18. Analyses were
performed separately for women with (i) borderline dys-
karyosis, (ii) a single mildly dyskaryotic cytology and
(iii) all women combined. We calculated test positivity,
PPV and sensitivity for CIN2+ and CIN3+ separately
for each triage strategy and the speciﬁcity for women
with <CIN2. Comparisons between tests were con-
ducted by McNemar’s test for matched pairs (Tables
S2 and S3).
All analyses were carried out using Stata 11.2 (Stata-
Corp, USA).
3. Results
A total of 1228 women were included from the two
Predictors studies. Of these, 941 (77%) were referred
with a single mildly dyskaryotic cytology and the
remaining 287 (23%) with borderline dyskaryosis (105/
287 (37%) with a single borderline dyskaryosis and
182/287 (63%) with multiple borderlines). Full details
are shown in Fig. 1. The age range of the women
included was from 18–67 years with a median age of
29 years (IQR 26–34 years).
The worst histology result within 9 months was CIN2
or worse for 203/1228 (17%) women with just under one
half of these being CIN3 or worse (97/1228, 7.9%).
There was a similar proportion of women with CIN3
or worse for those referred with a single mildly dyskar-
yotic smear and those with multiple borderlines (7.4%
versus 6.6%, respectively, p = 0.69). However, a referral
of single mild dyskaryosis was more associated with
CIN2 than multiple borderlines (11% versus 4.7%
p = 0.01). Full details of the worst histology result
according to referral cytology are shown in Table 1.Table 1
Results of referral smear and worst reviewed consensus h
Histology result Ref
Bor
No biopsy 77
Unsatisfactory 4 (1
Normal 63
Human papillomavirus (HPV) only/borderline 23
CIN I 82
CIN II 11
CIN III 20
CGIN high grade 4 (1
Invasive carcinoma 3 (1
Total 287The proportion of women with an inadequate result
varied by test. For Predictors phase I, p16INK4a cytology
was the last test to be performed on the sample and
hence there was not always suﬃcient material to prepare
a slide with adequate cellularity. Therefore, p16INK4a
had an adequate result for 73% of women, whereas all
other tests had an adequate result for between 96%
and 100%. Amongst those with an adequate result, pos-
itivity rates ranged from 73% to 80% for the DNA based
tests. Of the RNA based tests, APTIMA had a positivity
rate of 70% and PreTect HPV-Proofer was much lower
at 34%. p16INK4a was also less often positive than the
DNA based tests and APTIMA at 54% (Table 2). The
proportion testing positive amongst those positive on
other tests was lower for p16INK4a and PreTect HPV-
Proofer (range from 56–68% and 43–48%, respectively).
All other tests had a positivity ranging from 87% to 99%
amongst those positive for other tests.
Sensitivity, speciﬁcity and PPV of the diﬀerent testing
strategies are reported in Table 3 and summarised
graphically in Fig. 2. Five tests had a sensitivity of
99% or higher for CIN3+: Hybrid Capture 2, Abbott
RealTime, BD HPV, Cobas 4800 and APTIMA. All
these tests were signiﬁcantly more sensitive than
p16INK4a or PreTect HPV-Proofer alone but had a lower
speciﬁcity for <CIN2 (between 23.3% and 34.7%).
Requiring p16INK4a to be positive in addition to the
highly sensitive HPV tests increased speciﬁcity to
between 58.1% and 63.2% although sensitivity for
CIN3+ was reduced for each of the tests by around
15%. Furthermore, requiring either PreTect HPV-
Proofer or p16INK4a to be positive as well as the HPV
test gave lower speciﬁcity (52.6% to 58.7%) but with sen-
sitivities between 94.8% and 100%.
Type-speciﬁc genotyping reduced sensitivity for
CIN3+ further still (69.1% to 79.6% for type 16/18;
68.8% to 75.5% for type 16 only). However, testing using
16 or 18 reduced the proportion of women without
CIN2+ who tested positive to between 17.0% and
26.3%, while typing for 16 alone reduced the proportion
of test positive women without CIN2+ to 12.4–18.7%
with a higher PPV between 39.1% and 45.3%. Byistology within 9 months of the baseline cytology.
erral cytology
derline (%) Single mild (%) Total (%)
(27) 206 (22) 283 (23)
.4) 13 (1.4) 17 (1.4)
(22) 206 (22) 269 (22)
(8.0) 94 (10) 117 (9.5)
(29) 257 (27) 339 (28)
(3.8) 95 (10) 106 (8.6)
(7.0) 68 (7.2) 88 (7.2)
.4) 0 (0.0) 4 (0.3)
.0) 2 (0.2) 5 (0.4)
(100) 941 (100) 1228 (100)
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type 16 by one of the highly sensitive tests, the sensitiv-
ities for CIN3+ compared to HPV type 16 testing alone
to between 89.6% and 98.0% with the proportion of
women with <CIN2 testing positive between 38.1%
and 41.4%. Combining positivity of HPV type 16 or Pre-
Tect HPV-Proofer gave lower sensitivities (83.7% to
87.5%) but improved speciﬁcity (67.5–73.1%).
Table S1 shows performance of diﬀerent strategies
according to referral cytology result. The majority of
women were referred with a single mildly dyskaryotic
cytology, hence these results are similar to the overall
results although with a slightly lower speciﬁcity for
<CIN2. Approximately two-thirds of those referred
with a borderline smear had previous cervical
abnormalities.
There was a high concordance between the Abbott
RealTime PCR, BD HPV and Cobas 4800 assays, with
kappa values in excess of 0.85 for all pairwise compari-
sons (Table S2). There was also a good agreement com-
paring Hybrid Capture 2 and APTIMA with these other
HPV-DNA tests (kappa values ranging from 0.63 to
0.77) but PreTect HPV Proofer and p16INK4a were less
often positive. Kappa values for all tests for type 16 were
high, with kappa values above 0.8 (Table S3).4. Discussion
This study compared several diﬀerent tests in samples
taken at the same time to evaluate diﬀerent triage strat-
egies. An ideal triage test should ensure that women
with high-grade cervical disease are identiﬁed but avoid
unnecessary over-referral to colposcopy.
Other studies have considered one or more HPV tests
amongst women with low-grade cervical abnormalities
but none have directly compared such a broad range
of diﬀerent tests. The ASCUS-LSIL Triage Study
(ALTS) was a multi-centre clinical trial evaluating man-
agement strategies amongst 3488 women referred with
ASCUS and 1572 with LSIL. Women were randomly
assigned to immediate colposcopy, cytology or HPV
testing using Hybrid Capture 2.12 A high proportion
(83%) of women referred with LSIL tested positive for
HPV.4 The women referred with ASCUS had a similar
sensitivity to colposcopy but with approximately half
the number of colposcopic referrals.5
A study of 810 retrospectively collected samples of
ASC-US and LSIL cases (roughly comparable to bor-
derline and mild dsykaryosis) compared the perfor-
mance of p16INK4a with HPV testing (Hybrid Capture
2) on the same specimen.13 For p16INK4a cytology, the
sensitivity for CIN2+ was 92.6% and 92.2%, respectively
for ASC-US and LSIL and for HPV testing was 90.1%
and 95.7%, respectively. The speciﬁcity for CIN2 was
higher for p16INK4a than HPV testing (63.2% versus
37.8% for ASC-US and 37.3% versus 18.5% for LSIL).
Table 3
Sensitivity, speciﬁcity and PPV for diﬀerent Triage strategies for all women based on 203 cases of CIN2+ and 97 cases of CIN3+.
CIN2+ CIN3+
n Positive
N (%) n PPV Sensitivity Speciﬁcity n PPV Sensitivity
Single test HC2 1199 958 (79.9) 201 20.1 96.0 23.3 97 10.1 100.0
Abbott RealTime PCR 1173 855 (72.9) 200 22.2 95.0 31.7 96 11.2 100.0
BD HPV test 669 519 (77.6) 117 21.2 94.0 25.9 49 9.4 100.0
Cobas 4800 668 524 (78.4) 117 21.2 94.9 25.0 49 9.4 100.0
PreTect HPV proofer 1180 405 (34.3) 193 34.6 72.5 73.2 94 19.8 85.1
APTIMA 1225 858 (70.0) 203 22.3 94.1 34.7 97 11.2 99.0
p16INK4a 895 487 (54.4) 157 25.3 78.3 50.7 68 12.1 86.8
HPV testing with p16INK4a HC2 895 431 (48.2) 157 28.3 77.7 58.1 68 13.7 86.8
Abbott RealTime PCR 877 397 (45.3) 155 29.5 75.5 61.2 67 14.6 86.6
BD HPV test 589 256 (43.5) 105 30.5 74.3 63.2 43 14.1 83.7
Cobas 4800 588 258 (43.9) 105 30.6 75.2 62.9 43 14.0 83.7
PreTect HPV proofer 866 203 (23.4) 151 42.4 57.0 83.6 66 23.2 71.2
APTIMA 893 398 (44.6) 157 30.2 76.4 62.2 68 14.8 86.8
HPV testing with (PreTect HPV proofer or p16INK4a) HC2 1183 621 (52.5) 198 28.0 87.9 54.6 96 14.8 95.8
Abbott RealTime PCR 1156 587 (50.8) 196 28.8 86.2 56.5 95 15.5 95.8
BD HPV test 661 359 (54.3) 114 28.4 89.5 53.0 49 13.6 100.0
Cobas 4800 660 362 (54.8) 114 28.5 90.4 52.6 49 13.5 100.0
APTIMA 1206 588 (48.8) 199 29.3 86.4 58.7 96 15.5 94.8
Type 16/18 testing Abbott RealTime PCR 1172 339 (28.9) 200 33.9 57.5 77.0 96 21.2 75.0
BD HPV test 663 210 (31.7) 117 33.8 60.7 74.5 49 18.1 77.6
Cobas 4800 668 219 (32.8) 117 33.8 63.2 73.7 49 17.8 79.6
PreTect HPV proofer 1228 282 (23.0) 193 38.3 53.2 83.0 94 23.8 69.1
APTIMA* 598 192 (32.1) 108 33.3 59.3 73.9 46 17.7 73.9
Type 16 testing Abbott RealTime PCR 1172 274 (23.4) 200 39.1 53.5 82.8 96 24.1 68.8
BD HPV test 663 167 (25.2) 117 40.1 57.3 81.7 49 21.6 73.5
Cobas 4800 668 173 (25.9) 117 40.5 59.8 81.3 49 21.4 75.5
PreTect HPV proofer 1180 223 (18.9) 193 45.3 52.3 87.6 94 27.8 66.0
APTIMA 598 144 (24.1) 108 41.7 55.6 82.9 46 22.9 71.7
Type 16 or p16INK4a Abbott RealTime PCR 1173 530 (45.2) 200 30.0 79.5 61.9 96 16.2 89.6
BD HPV test 667 326 (48.9) 117 30.7 85.5 58.9 49 14.7 98.0
Cobas 4800 668 329 (49.3) 117 30.7 86.3 58.6 49 14.6 98.0
PreTect HPV proofer 1180 311 (26.4) 193 41.2 66.3 81.5 94 23.8 78.7
APTIMA 965 457 (47.4) 168 30.6 83.3 60.2 74 15.5 95.9
Type 16 or PreTect HPV proofer Abbott RealTime PCR 1173 439 (37.4) 200 33.0 72.5 69.8 96 19.1 87.5
BD HPV test 669 265 (39.6) 117 32.5 73.5 67.6 49 15.5 83.7
Cobas 4800 668 266 (39.8) 117 32.7 74.4 67.5 49 15.4 83.7
APTIMA 1206 416 (34.5) 200 34.9 72.5 73.1 96 19.7 85.4
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ity for p16INK4a testing than we have shown. However,
within Predictors 1, as the p16INK4a testing was the last
to be evaluated, the high number of inadequate samples
due to insuﬃcient material should mean that these
results are interpreted with caution. For Predictors 2
alone, p16INK4a had a valid result for 589/669 (88%)
of samples with 76.2% sensitivity for CIN2+ (83.7%
for CIN3+) and 57.2% speciﬁcity.
The ATHENA study6 compared Hybrid Capture 2
with Cobas 4800 in 1923 women with ASC-US cytology.
The Cobas 4800 HPV test had a comparable perfor-
mance for CIN2+ compared with the Hybrid Capture
2 test (sensitivity 90.0% vs. 87.2%; speciﬁcity 70.5% vs.
71.1%, respectively). Positivity for the two tests was con-
siderably lower than seen in our study almost certainly
due to the fact that this population included women
with only a single ASC-US cytology (the majority of
women in our study were referred with multiple border-
line smears or a mildly dyskaryotic smear).
In this study, ﬁve HPV tests alone (Hybrid Capture 2,
Abbott RealTime PCR, BD HPV test, Cobas 4800,
APTIMA) had a very high sensitivity when considered
in a triage setting ranging from 99% to 100% for
CIN3+. These highly sensitive tests have a lower speci-
ﬁcity but could reduce the number of referrals to colpos-
copy, in the population of women currently referred, by
20% to 30%. We also found that speciﬁcity improved by
another 20–30% if only referring women testing positive
for HPV type 16 or p16INK4a. This strategy had little
impact on sensitivity for CIN3+ although sensitivity
for CIN2+ was slightly reduced. Other, less sensitive tri-
age tests (p16INK4a and PreTect HPV-Proofer) couldreduce the number of unnecessary referrals by a further
15–25% but miss between 15% and 30% of CIN3+. It is
known that many CIN2 and some CIN3 lesions will
regress spontaneously and it cannot be excluded that
tests with lower sensitivity still identify those lesions
which are destined to progress to cancer. Nevertheless,
these strategies would need to be combined with early
recall when tests are negative. Since in the NHSCSP tri-
age protocol women who have a negative HPV test will
be returned to routine (three or ﬁve yearly screening), it
is important that disease is not missed. If HPV was the
primary screen then further testing amongst HPV posi-
tive women for HPV high-risk type 16 and p16INK4a
may be important strategies to determine which women
to refer to colposcopy, especially amongst those with a
negative cytology.
This study included only women from Predictors 1
and Predictors 210,11 who had been referred to colpos-
copy with low-grade abnormalities and does not address
women with low-grade abnormalities who were not
referred (such as those with a single borderline dyskary-
otic cytology). Triage of these women with the above
tests is likely to increase referrals to colposcopy but this
has not been addressed in this study. In the new propos-
als from the NHSCSP women with a single cytology
showing borderline dyskaryosis would receive further
HPV testing and are likely to have a lower rate of dis-
ease than women in this study. One further limitation
of this study is that HPV testing did not aﬀect future
screening of the women and we have no subsequent test
results. A recent study published by Rijkaart et al.14
compared 14 diﬀerent triage strategies for HPV-DNA
positive women with combinations of further cytology
2186 D. Mesher et al. / European Journal of Cancer 49 (2013) 2179–2186and HPV testing strategies. Triage of HPV positive
women with cytology, followed by repeat cytology
yielded a high negative predictive value and modest col-
poscopy referral rate.
This study adds to further publications of these data
and allows direct comparison of tests and combinations
of tests in a triage setting. We have shown that ﬁve HPV
tests had a very high sensitivity when considered in this
setting and could still reduce the number of referrals to
colposcopy by 20–30%. Other triage strategies could
reduce the number of unnecessary referrals further but
with a lower sensitivity for CIN3+ which would require
combination with an earlier recall for screening.
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